Appointment at FLORetina 2019 for a 360° update on the most advanced treatments
FLORetina is a biennial event, featuring leading Italian and European retina specialists.
This year, the event, now in its third edition, will be held from 6 to 9 June in the beautiful city of Florence and is intended to be an important moment of international comparison and updating.
The scientific programme features presentations on state-of-the-art surgical techniques, live surgery and interventional medicine treatments, the pros and cons of which will be debated.
Events include a symposium on 8 June comparing European and American clinical experience in the treatment of Diabetic Macular Oedema.
DME PATIENTS: REAL LIFE EXPERIENCE WITH FLUOCINOLONE ACETONIDE FROM BOTH SIDES OF THE ATLANTIC
F. Bandello
PROGRAMME:
- Three year data from Germany with fluocinolone acetonide A. Augustin
- Advantage of continuous microdosing: San Raffaele hospital experience F. Bandello
- US real world data with fluocinolone acetonide J. Kim
- Discussion
8 June 2019
10:00 a.m. - 11:00 a.m.
SALA Onice Palazzo dei Congressi - Florence
EMD treatment options
To date, there are several therapeutic strategies capable of slowing down the course of EMD, which are also indicated by national guidelines.
Among the first-line treatments for the form of EMD that does not involve the centre of the retina is the laser photocoagulationa well-established technique in the management of the disease. However, this approach may be associated with side effects, such as the possibility of some scarring in the retinal area.
For the treatment of EMD affecting the macular area, however, the administration of intravitreal drugs, known as anti-VEGF agents (VEGF, vascular endothelial growth factor), which is able to counteract the massive production of vascular endothelial growth factor, and thus counteract the growth of neovases and thus slow down and improve the pathological condition. However, in this case, it is necessary to undergo a large number of annual intravitreal injections and doctor visits.
For all those who cannot be treated with anti-VEGF drugs or who have not responded adequately to first-line treatments, the guidelines indicate the intravitreal administration of corticosteroidsand among them the fluocinolone acetonide (FAc).
Treatment of Diabetic Macular Oedema: from the past to the present day
Mediators of inflammation in diabetic macular oedema
Dr. Carmelo Chines
Direttore responsabile
English 
Italian